Exploring DMT: Endogenous role and therapeutic potential.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and mechanistic literature with no new human empirical data.
PubMed 39832530 · doi:10.1016/j.neuropharm.2025.110314
What was done
This review synthesized literature on the biosynthesis, degradation, and biological roles of endogenous N,N-dimethyltryptamine (DMT). The authors evaluated DMT synthetic pathways centered on indolethylamine N-methyltransferase (INMT) and its isoforms, alternative methylation routes, degradation via monoamine oxidase (MAO), and the influence of physiological stressors such as hypoxia. They examined cellular targets, including intracellular 5-HT2A receptors, and evaluated DMT's proposed roles in neuroplasticity, neurogenesis, mitochondrial homeostasis, and immunomodulation.
What was found
The abstract reports no quantitative metrics or effect sizes. It qualitatively describes findings that DMT reaches concentrations in rodent brains comparable to classical neurotransmitters, enters cells due to its lipophilic properties to engage intracellular 5-HT2A receptors, and promotes cellular protection during oxidative stress and hypoxia.
Why it matters
This paper synthesizes emerging evidence that DMT may act as a functional endogenous neuromodulator and intracellular signaling ligand rather than merely a trace metabolic byproduct. Clarifying these endogenous mechanisms helps frame its therapeutic potential.
Limits
The paper is a non-systematic narrative review. The discussed mechanisms rely primarily on rodent, in vitro, and bench models, limiting direct translation to human physiology. The abstract provides no primary empirical data, sample sizes, or quantitative meta-analytic synthesis.
Cited by
- context Specific breathing techniques can stimulate the endogenous production of DMT (N,N-dimethyltryptamine).